Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023)

Mira Pharmaceuticals' (MIRA) quarterly Debt to Equity came in at $1.51 in Q2 2023, up 775.14% quarter-over-quarter from -$0.22 in Q4 2022.

Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023) Analysis & Trends

Mira Pharmaceuticals has disclosed Debt to Equity across 2 years of filings, most recently posting $1.51 for Q2 2023.

Debt to Equity for Q2 2023 came in at $1.51, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $1.51 (changed N/A YoY), and the FY2022 annual result was -$0.22, changed N/A from the prior year.
Debt to Equity came in at $1.51 for Q2 2023 at Mira Pharmaceuticals, up from -$0.22 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $1.51 in Q2 2023 to a low of -$0.22 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	1.39
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	0.68
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-9.70
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	1.07
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	6.24
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	0.94
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	0.72
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	2.22
10	Mira Pharmaceuticals	22.73 Mn	11.70 Mn	-	-

Download Data

Date	Value
Jun 30, 2023	1.51
Dec 31, 2022	-0.22